Sanofi CEO Paul Hudson highlighted the pharmaceutical company's use of AI to determine whether drugs should advance to the next development phase during a panel at Davos. Hudson described the sobering nature of relying on AI, noting that it operates without career stakes unlike senior decision-makers, allowing for more objective evaluations. AI has been a part of Sanofi's drug discovery process for about three years, significantly contributing to the lengthy, typically 12 to 15-year cycle of drug development and testing.
Sanofi uses AI to recommend whether drugs should pass through a tollgate into the next development phase, leveraging dispassionate evaluation over human attachment.
Hudson emphasized AI’s role in decision-making at Sanofi, noting it approaches drug evaluations without career stakes, providing an unbiased perspective in a senior-level context.
Collection
[
|
...
]